DYN earnings analysis
What we found in DYN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Dyne remains pre-revenue, with Q2 2026 net loss widening to $178.6 million from $110.9 million a year earlier as R&D spending rose to $152.2 million to support DMD and DM1 registrational programs. The operating picture is cash-intensive—six-month operating cash use reached $275.2 million—but $898.5 million of June liquidity plus approximately $405.0 million of July equity proceeds is expected to fund operations into Q2 2028. The key near-term value driver is the priority-review z-rostudirsen BLA, with a January 21, 2027 PDUFA date and a potential Q1 2027 launch if approved.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Z-rostudirsen BLA has Jan. 2027 action date
- The company reported no revenue, consistent with its clinical-stage status, but the FDA accepted the z-rostudirsen BLA with priority review and assigned a January 21, 2027 PDUFA target action date. Management continues to expect a potential U.S. launch in Q1 2027, subject to approval.
- Loss and operating spend accelerated
- Q2 net loss widened 61.1% year over year to $178.6 million from $110.9 million, while operating expenses rose 56.9% to $181.7 million. Sequentially, Q2 net loss increased 47.8% from the implied Q1 2026 loss of $120.9 million.
- DMD and DM1 investment rose sharply
- DMD program R&D expense rose $22.8 million year over year to $52.3 million in Q2, driven by manufacturing and the Phase 3 FORZETTO trial. DM1 program R&D increased $14.3 million to $49.0 million as ACHIEVE enrollment completed and HARMONIA enrollment expanded.
- Liquidity runway extends into Q2 2028
- Cash, cash equivalents and marketable securities were $898.5 million at June 30, 2026; the July equity offering subsequently added estimated net proceeds of approximately $405.0 million. Management states this liquidity funds operating expenses, debt service and capex into Q2 2028.
- Operating cash burn increased; capex remains low
- Six-month operating cash use increased 37.2% to $275.2 million from $200.6 million. Capex was modest at $1.7 million, or approximately 0.6% of operating cash use, during the first six months of 2026; free cash flow was not explicitly reported.
- Multiple late-stage and pipeline milestones
- Pipeline execution advanced: the Phase 3 FORZETTO trial began in May 2026, HARMONIA began dosing in July 2026, and the FDA cleared the DYNE-302 FSHD IND in July 2026. The ACHIEVE registrational expansion cohort completed enrollment of 71 participants, with data planned for Q1 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Growing cash burn despite extended runway
- Losses and cash use are rising: the six-month net loss increased to $299.4 million from $226.2 million, while operating cash use was $275.2 million. Although management projects runway into Q2 2028, it warns that capital could be exhausted sooner and additional financing may be required.
- Equity dilution and conditional debt capacity
- Financing and leverage have increased. The company issued 21,045,000 shares in July 2026 for estimated net proceeds of $405.0 million, while term-loan principal was $200.0 million at June 30, 2026; remaining loan availability is contingent on milestones or lender discretion.
- New tariff and supply-chain policy exposure
- The filing adds heightened trade-policy exposure: a 100% Section 232 tariff on covered patented pharmaceuticals, biologics and ingredients is scheduled to apply from September 29, 2026 for companies without qualifying exemptions. The company also cites a June 2026 designation of one CDMO under the BIOSECURE Act framework, though it does not currently expect an impact.
- Large manufacturing commitments raise execution risk
- Manufacturing commitments are substantial and potentially non-cancelable: one CMO arrangement has $99.7 million committed through June 2028 and another has $59.8 million committed through December 2027. Manufacturing is projected to represent 55-65% of full-year 2026 R&D expense.
- Registrational trials still carry high execution risk
- Clinical and regulatory risk remains central despite expedited designations. FORZETTO plans to enroll approximately 90 participants and HARMONIA approximately 150 participants, while the company has never completed clinical development of a product candidate or generated product revenue.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects no product-sales revenue until at least 2027, if at all; it expects available cash plus approximately $405.0 million of July offering proceeds to fund operations into Q2 2028. For full-year 2026, manufacturing costs are projected at 55-65% of R&D expense and clinical-trial costs at 10-20%.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Dyne Therapeutics reported a net loss of approximately $120.9 million for Q1 2026, slightly increasing from a loss of $115.4 million in Q1 2025, amid continued development efforts in their clinical programs. Key focus…
- 10-K · March 2, 2026
- Dyne is a clinical‑stage, pre‑revenue biotech building a modular FORCE TfR1 delivery platform and advancing co‑lead registrational programs in DMD (z‑rostudirsen) and DM1 (z‑basivarsen). The 10‑K outlines clear…
- 10-Q · November 5, 2025
- Dyne remains pre-revenue and cash consumptive but materially strengthened liquidity in 2025 Q3 after equity raises and a new debt facility. Q3 net loss was $108.0M (‑$0.76 per share), slightly improved versus Q2 2025…
- 10-Q · July 28, 2025
- Dyne remains a pre-revenue, clinical‑stage company with rising R&D spend and larger quarterly losses; Q2 net loss widened to $(110,857) (net loss per share $(0.97)) versus $(65,102) ($(0.70)) year‑ago. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DYN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever